These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29055468)

  • 1. Evaluation of lithium serum level in multiple sclerosis patients: A neuroprotective element.
    Karimi A; Bahrampour K; Momeni Moghaddam MA; Asadikaram G; Ebrahimi G; Torkzadeh-Mahani M; Esmaeili Tarzi M; Nematollahi MH
    Mult Scler Relat Disord; 2017 Oct; 17():244-248. PubMed ID: 29055468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Yuceyar N; Taşkiran D; Sağduyu A
    Clin Neurol Neurosurg; 2001 Dec; 103(4):206-11. PubMed ID: 11714562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis.
    Ortiz GG; Macías-Islas MA; Pacheco-Moisés FP; Cruz-Ramos JA; Sustersik S; Barba EA; Aguayo A
    Dis Markers; 2009; 26(1):35-9. PubMed ID: 19242067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.
    Rejdak K; Petzold A; Kocki T; Kurzepa J; Grieb P; Turski WA; Stelmasiak Z
    J Neural Transm (Vienna); 2007; 114(8):1011-5. PubMed ID: 17393066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and cerebrospinal fluid concentrations of homoarginine, arginine, asymmetric and symmetric dimethylarginine, nitrite and nitrate in patients with multiple sclerosis and neuromyelitis optica.
    Haghikia A; Kayacelebi AA; Beckmann B; Hanff E; Gold R; Haghikia A; Tsikas D
    Amino Acids; 2015 Sep; 47(9):1837-45. PubMed ID: 26055922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid level in patients with relapsing-remitting multiple sclerosis.
    Ashtari F; Bahar M; Aghaei M; Zahed A
    J Clin Neurosci; 2013 May; 20(5):676-8. PubMed ID: 23528410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis.
    Orefice N; Carotenuto A; Mangone G; Bues B; Rehm R; Cerillo I; Saccà F; Calignano A; Orefice G
    J Steroid Biochem Mol Biol; 2016 May; 159():1-7. PubMed ID: 26892094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of nitric oxide metabolites in the serum of Iranian multiple sclerosis patients.
    Roghani M; Mahboudi F; Saharian MA; Etemadifar M; Esfahani AN; Nahrevanian H; Elahi E
    J Neurol Sci; 2010 Jul; 294(1-2):92-4. PubMed ID: 20434172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity.
    Drulović J; Dujmović I; Mesaros S; Samardzić T; Maksimović D; Stojsavljević N; Lević Z; Mostarica Stojokvić M
    Mult Scler; 2001 Feb; 7(1):19-22. PubMed ID: 11321188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
    Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
    Stojanovic I; Vojinovic S; Ljubisavljevic S; Pavlovic R; Basic J; Pavlovic D; Ilic A; Cvetkovic T; Stukalov M
    J Neurol Sci; 2012 Dec; 323(1-2):187-92. PubMed ID: 23026532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide as an activity marker in multiple sclerosis.
    Acar G; Idiman F; Idiman E; Kirkali G; Cakmakçi H; Ozakbaş S
    J Neurol; 2003 May; 250(5):588-92. PubMed ID: 12736739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes.
    Alatab S; Maghbooli Z; Hossein-Nezhad A; Khosrofar M; Mokhtari F
    Minerva Med; 2011 Dec; 102(6):461-8. PubMed ID: 22193377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA 26a Expression in Peripheral Blood Mononuclear Cells and Correlation with Serum Interleukin-17 in Relapsing-Remitting Multiple Sclerosis Patients.
    Mahmoud FM; ElSheshtawy NM; Zaki WK; Zamzam DM; Fahim NM
    Egypt J Immunol; 2017 Jun; 24(2):71-82. PubMed ID: 29528581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum nitric oxide metabolites in patients with multiple sclerosis.
    Nazliel B; Taşkiran D; Irkec C; Kutay FZ; Pöğün S
    J Clin Neurosci; 2002 Sep; 9(5):530-2. PubMed ID: 12383409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.
    Gresle MM; Liu Y; Dagley LF; Haartsen J; Pearson F; Purcell AW; Laverick L; Petzold A; Lucas RM; Van der Walt A; Prime H; Morris DR; Taylor BV; ; Shaw G; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1209-13. PubMed ID: 24639436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
    Oliveira SR; Kallaur AP; Reiche EMV; Kaimen-Maciel DR; Panis C; Lozovoy MAB; Morimoto HK; Maes M; Dichi I; Simão ANC
    Mol Neurobiol; 2017 May; 54(4):2961-2968. PubMed ID: 27026183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.